Requip News
Teva announces tentative approval of generic Requip® tablets - Prdomain Business Register (press release)
Upon final approval, Teva's product will be the AB-rated generic equivalent of Requip® Tablets, and will be indicated for the treatment of the signs and ...
Restless legs can make for a long night - Chicago Daily Herald
I suggest you ask your doctor to prescribe a course of therapy using Requip, a new medicine that treats RLS. Q. I am a 65-year-old female with periodic ...
UPDATE: Skyepharma Up As Flutiform Inches Closer To Market - CNNMoney.com
LN) Requip XL, a once-a-day reformulation of Parkinson's disease treatment Requip, developed using Skyepharma's technology. Still, they remain about 40% ...
UPDATE: Skyepharma Up As Flutiform Inches Closer To Market - CNNMoney.com
LN) Requip XL, a once-a-day reformulation of Parkinson's disease treatment Requip, developed using Skyepharma's technology. Still, they remain about 40% ...
SykePharma Gains FDA Approval For Parkinson's Drug Reformulation - Wall Street Journal
Requip XL, a once-daily reformulation of Parkinson's disease treatment Requip, was developed using SkyePharma's technology. The London-based company uses ...
SkyePharma says FDA gives approvable letter for GlaxoSmithKline's ... - Hemscott
LONDON (Thomson Financial) - SkyePharma has announced that the US Food and Drug Administration has issued an approvable letter for GlaxoSmithKline's Requip ...
US FDA delays approval of Glaxo's Requip XL - Reuters
L: Quote, Profile, Research) Requip drug for Parkinson's disease, Europe's biggest drugmaker said on Monday. Glaxo said it had received a so-called ...
Glaxo drops bid to sell Requip CR in leg disorder - Reuters
L: Quote, Profile, Research) said on Monday it would not pursue plans to sell a controlled release version of its drug Requip, known as Requip CR, ...
UPDATE 1-Glaxo's Requip drug suffers US setback - Reuters
L: Quote, Profile, Research) to market two long-lasting versions of its Requip medicine in the United States suffered a double blow on Monday. ...
GSK enters into $1.4 billion cancer pact with OncoMed - Pharma Times (subscription)
GSK also noted that it has decided not to pursue an application to market Requip CR, a controlled-release formulation of the drug, for the treatment of ...
Requip RSS Feed